Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Kakolyris S, Souglakos J, Polyzos A, Ardavanis A, Ziras N, Athanasiadis A, Varthalitis I, Amarantidis K, Tsousis S, Vamvakas L, Vardakis N, Georgoulias V; Hellenic Oncology Research Group. Kakolyris S, et al. Among authors: vardakis n. Oncology. 2008;74(1-2):31-6. doi: 10.1159/000138977. Epub 2008 Jun 10. Oncology. 2008. PMID: 18544957 Clinical Trial.
Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer.
Souglakos J, Androulakis N, Mavroudis D, Kourousis C, Kakolyris S, Vardakis N, Kalbakis K, Pallis A, Ardavanis A, Varveris C, Georgoulias V. Souglakos J, et al. Among authors: vardakis n. Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1284-7. doi: 10.1016/s0360-3016(03)00275-x. Int J Radiat Oncol Biol Phys. 2003. PMID: 12873672 Clinical Trial.
A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer.
Agelaki S, Syrigos K, Christophylakis C, Boukovinas J, Varthalitis J, Pavlakou G, Athanasiadis A, Kouroussis C, Vardakis N, Maltezakis G, Milaki G, Georgoulias V; Lung Cancer Subgroup, Hellenic Oncology Research Group. Agelaki S, et al. Among authors: vardakis n. Oncology. 2004;66(3):192-6. doi: 10.1159/000077994. Oncology. 2004. PMID: 15218309 Clinical Trial.
Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study.
Kakolyris S, Ziras N, Vamvakas L, Varthalitis J, Papakotoulas P, Syrigos K, Vardakis N, Kalykaki A, Amarantidis K, Georgoulias V. Kakolyris S, et al. Among authors: vardakis n. Lung Cancer. 2006 Dec;54(3):347-52. doi: 10.1016/j.lungcan.2006.09.001. Epub 2006 Oct 9. Lung Cancer. 2006. PMID: 17030075 Clinical Trial.
Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Kalykaki A, Papakotoulas P, Tsousis S, Boukovinas I, Kalbakis K, Vamvakas L, Kotsakis A, Vardakis N, Papadopoulou P, Georgoulias V, Mavroudis D; Hellenic Oncology Research Group. Kalykaki A, et al. Among authors: vardakis n. Anticancer Res. 2008 Jan-Feb;28(1B):495-500. Anticancer Res. 2008. PMID: 18383891 Free article. Clinical Trial.
74 results